These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 25631854)

  • 1. AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game.
    Canaud G; Legendre C; Terzi F
    Lupus; 2015 Mar; 24(3):227-30. PubMed ID: 25631854
    [No Abstract]   [Full Text] [Related]  

  • 2. [New insights in the antiphospholipid syndrome associated vasculitis: the role of the AKT/mTORC pathway].
    Canaud G
    Rev Med Interne; 2015 Jul; 36(7):439-43. PubMed ID: 25769629
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Canaud G; Bienaimé F; Tabarin F; Bataillon G; Seilhean D; Noël LH; Dragon-Durey MA; Snanoudj R; Friedlander G; Halbwachs-Mecarelli L; Legendre C; Terzi F
    N Engl J Med; 2014 Jul; 371(4):303-12. PubMed ID: 25054716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report.
    Dufour I; Venot Q; Aydin S; Demoulin N; Canaud G; Morelle J
    Am J Kidney Dis; 2020 Aug; 76(2):288-291. PubMed ID: 31810732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mTORC pathway in the antiphospholipid syndrome.
    Eikelboom JW; Weitz JI
    N Engl J Med; 2014 Jul; 371(4):369-71. PubMed ID: 25054721
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Van Laecke S; Nagler EV; Vanholder R
    N Engl J Med; 2014 Oct; 371(16):1553. PubMed ID: 25317878
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Canaud G; Terzi F
    N Engl J Med; 2014 Oct; 371(16):1554-5. PubMed ID: 25317877
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Zuily S; Regnault V; Wahl D
    N Engl J Med; 2014 Oct; 371(16):1553-4. PubMed ID: 25317879
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of the mTORC pathway in the antiphospholipid syndrome.
    Hidalgo LG
    N Engl J Med; 2014 Oct; 371(16):1554. PubMed ID: 25317880
    [No Abstract]   [Full Text] [Related]  

  • 10. Cellular repressor of E1A-stimulated genes regulates vascular endothelial cell migration by the ILK/AKT/mTOR/VEGF(165) signaling pathway.
    Zhang H; Han Y; Tao J; Liu S; Yan C; Li S
    Exp Cell Res; 2011 Dec; 317(20):2904-13. PubMed ID: 21939655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Connective tissue diseases: mTORC is a potential therapeutic target in APS.
    Duarte JH
    Nat Rev Nephrol; 2014 Oct; 10(10):544. PubMed ID: 25092152
    [No Abstract]   [Full Text] [Related]  

  • 12. Connective tissue diseases: mTORC is a potential therapeutic target in APS.
    Duarte JH
    Nat Rev Rheumatol; 2014 Sep; 10(9):513. PubMed ID: 25090943
    [No Abstract]   [Full Text] [Related]  

  • 13. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
    Quesada AE; Nguyen ND; Rios A; Brown RE
    Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The PI3K-AKT-mTOR pathway as a target in cancer therapeutics].
    Hirao A
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():57-62. PubMed ID: 23513812
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitory effect of 14,15-EET on endothelial senescence through activation of mTOR complex 2/Akt signaling pathways.
    Yang C; Pan S; Yan S; Li Z; Yang J; Wang Y; Xiong Y
    Int J Biochem Cell Biol; 2014 May; 50():93-100. PubMed ID: 24607498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
    Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
    Br J Haematol; 2015 May; 169(3):455-8. PubMed ID: 25407287
    [No Abstract]   [Full Text] [Related]  

  • 17. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL.
    Hutter G; Zimmermann Y; Rieken M; Hartmann E; Rosenwald A; Hiddemann W; Dreyling M
    Leukemia; 2012 Nov; 26(11):2442-4. PubMed ID: 22552006
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells.
    Kim GD; Oh J; Park HJ; Bae K; Lee SK
    Int J Oncol; 2013 Aug; 43(2):600-10. PubMed ID: 23708970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt/mTOR signalling in myelination.
    Norrmén C; Suter U
    Biochem Soc Trans; 2013 Aug; 41(4):944-50. PubMed ID: 23863161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.